The logo of Danish pharmaceutical company Novo ... said its experimental diabetes and weight-loss drug CagriSema fell short of expectations. The drug did not achieve the projected 25% average ...

The company said a Phase 3 trial showed that after 68 weeks, those who took CagriSema achieved a weight loss of 15.7%, compared with a weight loss of 3.1% for those taking a placebo. Tomi Kilgore ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...

Novo Nordisk A/S' CagriSema disappointed investors again, but today's update should not have surprised anyone. The flexible dosing protocol in the REDEFINE trials likely led to suboptimal efficacy ...

Novo reported that, in a late-stage study, a next-generation obesity drug called CagriSema led patients to lose 20% of their weight at 68 weeks when looking at all participants — less than the ...

which is “what we expected in this data scenario,” as CagriSema weight loss data is not as differentiated compared to Eli Lilly’s (LLY) Zepbound as was expected. Weight loss in the REDEFINE ...